Press Releases

Mitomics Announces U.S. Sales and Marketing Agreement with Sterling Pathology
"Diagnostic pathology firm to offer breakthrough prostate cancer assay to urology market"
 
Thunder Bay, Ontario, Canada, January 7, 2013 /CNW/ – Mitomics, a developer of mitochondrial 
DNA-based tests for early disease detection, today announced it has entered into a sales and 
marketing agreement for the Prostate Core Mitomic Test™  (PCMT™) with Sterling Pathology National  
Laboratories.  Under  the  agreement,  Sterling  Pathology National Laboratories, a leader in 
diagnostic pathology services, will make PCMT available through their team of sales representatives 
to urologists throughout the United States, on a non-exclusive basis. PCMT is one of the most 
accurate and safest tests currently on the market for the detection of prostate cancer... Read More